I agree that this site is using cookies. You can find further informations here.
X
Lepik, K.
104  results:
Search for persons X
?
1

THE OUTCOME OF GLOFITAMAB THERAPY IN PATIENTS WITH AGGRESSI..:

Fedorova, L. ; Smykova, O. ; Lepik, K....
Hematological Oncology.  41 (2023)  S2 - p. 715-715 , 2023
Link: https://doi.org/10.1002/..
 
?
2

97P Toxicity of bispecific antibody glofitamab in patients ..:

Fedorova, L. ; Smykova, O. ; Chekalov, A....
Immuno-Oncology and Technology.  16 (2022)  - p. 100201 , 2022
Link: https://doi.org/10.1016/..
 
?
3

P1080: COMPARISON OF NIVOLUMAB 40 MG EFFICACY VERSUS 3 MG/K..:

Fedorova, L. ; Lepik, K. ; Mikhailova, N....
HemaSphere.  6 (2022)  - p. 970-971 , 2022
Link: https://doi.org/10.1097/..
 
?
4

P1077: HODGKIN LYMPHOMA IN PATIENTS WITH HIV: NATIONAL RETR..:

Chekalov, A. ; Popova, M. ; Tsygankov, I....
HemaSphere.  6 (2022)  - p. 967-968 , 2022
Link: https://doi.org/10.1097/..
 
?
5

BRENTUXIMAB VEDOTIN FOR TREATMENT IN PATIENTS WITH RELAPSED..:

Ionova, T. ; Andrievskikh, M. ; Amdiev, A....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
6

RESPONSE TO NIVOLUMAB AS ≥3rd LINE THERAPY IN PTS WITH RELA..:

Lepik, K. ; Mikhaylova, N. ; Kondakova, E....
Hematological Oncology.  37 (2019)  S2 - p. 495-495 , 2019
Link: https://doi.org/10.1002/..
 
?
7

INFECTIOUS COMPLICATIONS OF NIVOLUMAB THERAPY IN RELAPSED/R..:

Rogacheva, Y. ; Popova, M. ; Lepik, K....
Hematological Oncology.  37 (2019)  S2 - p. 502-502 , 2019
Link: https://doi.org/10.1002/..
 
?
8

RETREATMENT WITH NIVOLUMAB IN PATIENTS WITH R/R CLASSICAL H..:

Fedorova, L. ; Lepik, K. ; Mikhailova, N....
Hematological Oncology.  37 (2019)  S2 - p. 496-497 , 2019
Link: https://doi.org/10.1002/..
 
?
9

CASE SERIES OF NIVOLUMAB TREATMENT IN PATIENTS WITH RELAPSE..:

Rogacheva, Y. ; Popova, M. ; Nekrasova, A....
Hematological Oncology.  37 (2019)  S2 - p. 500-502 , 2019
Link: https://doi.org/10.1002/..
 
?
10

TREATMENT OF RELAPSED AND REFRACTORY T‐CELL LYMPHOMAS: FIRS..:

Lepik, E. ; Kozlov, A. ; Borzenkova, E....
Hematological Oncology.  37 (2019)  S2 - p. 473-474 , 2019
Link: https://doi.org/10.1002/..
 
?
11

Declines in highly active antiretroviral therapy initiation..:

Lourenço, L ; Samji, H ; Nohpal, A...
HIV Medicine.  16 (2015)  6 - p. 337-345 , 2015
Link: https://doi.org/10.1111/..
 
?
12

Benefit Sensitivities of Adaptive Traffic Control Strategie..:

Stewart, J.A. ; Lepik, K. ; Van Aerde, M.
Transportation Research Record: Journal of the Transportation Research Board.  1692 (1999)  1 - p. 173-181 , 1999
Link: https://doi.org/10.3141/..
 
?
13

Muscarinic (m5) receptors in the ventral tegmental area are..:

Yeomans, J.S. ; Takeuchi, J. ; Baptista, M....
Life Sciences.  60 (1997)  13-14 - p. 1203 , 1997
Link: https://doi.org/10.1016/..
 
?
14

COMBINATION OF NIVOLUMAB AND BENDAMUSTINE IN PATIENTS WITH ..:

Mikhailova, N.B. ; Lepik, K.V. ; Kondakova, E.V....
Hematological Oncology.  37 (2019)  S2 - p. 494-495 , 2019
Link: https://doi.org/10.1002/..
 
?
15

Efficacy of Dasatinib in a CML Patient in Blast Crisis with..:

Morozova, E.V. ; Vlasova, Y.Y. ; Pryanishnikova, M.V...
Biomarker Insights.  10s3 (2015)  - p. BMI.S22438 , 2015
Link: https://doi.org/10.4137/..
 
1-15